EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics


EyePoint Pharmaceuticals, Inc. (EYPT): $3.39

0.19 (+5.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EYPT POWR Grades

  • EYPT scores best on the Sentiment dimension, with a Sentiment rank ahead of 79.44% of US stocks.
  • EYPT's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • EYPT ranks lowest in Quality; there it ranks in the 18th percentile.

EYPT Stock Summary

  • EYEPOINT PHARMACEUTICALS INC's market capitalization of $109,065,389 is ahead of only 20.25% of US-listed equities.
  • In terms of volatility of its share price, EYPT is more volatile than 81.61% of stocks we're observing.
  • EYEPOINT PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -99.72%, greater than the shareholder yield of only 5.95% of stocks in our set.
  • Stocks that are quantitatively similar to EYPT, based on their financial statements, market capitalization, and price volatility, are ONDS, AAOI, NSPR, WISA, and MRIN.
  • EYPT's SEC filings can be seen here. And to visit EYEPOINT PHARMACEUTICALS INC's official web site, go to eyepointpharma.com.

EYPT Valuation Summary

  • EYPT's price/sales ratio is 2.7; this is 35% higher than that of the median Healthcare stock.
  • EYPT's EV/EBIT ratio has moved up 125.8 over the prior 217 months.

Below are key valuation metrics over time for EYPT.

Stock Date P/S P/B P/E EV/EBIT
EYPT 2022-11-25 2.7 0.8 -1.4 -1.1
EYPT 2022-11-23 2.7 0.8 -1.5 -1.1
EYPT 2022-11-22 2.7 0.9 -1.5 -1.2
EYPT 2022-11-21 2.8 0.9 -1.5 -1.2
EYPT 2022-11-18 2.9 0.9 -1.6 -1.3
EYPT 2022-11-17 3.0 0.9 -1.6 -1.3

EYPT Growth Metrics

    Its 4 year cash and equivalents growth rate is now at 123.48%.
  • Its 4 year price growth rate is now at -53.35%.
  • Its 2 year price growth rate is now at 28.28%.
Over the past 33 months, EYPT's revenue has gone up $22,050,000.

The table below shows EYPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 42.415 -69.085 -78.234
2022-06-30 41.462 -63.736 -76.509
2022-03-31 38.91 -55.156 -67.113
2021-12-31 36.939 -50.097 -58.417
2021-09-30 32.526 -27.534 -54.454
2021-06-30 39.162 -18.611 -41.56

EYPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EYPT has a Quality Grade of C, ranking ahead of 30.89% of graded US stocks.
  • EYPT's asset turnover comes in at 0.293 -- ranking 58th of 75 Measuring and Control Equipment stocks.
  • BRKR, HURC, and ONTO are the stocks whose asset turnover ratios are most correlated with EYPT.

The table below shows EYPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.293 0.804 -0.673
2021-03-31 0.322 0.818 -0.674
2020-12-31 0.433 0.831 -0.636
2020-09-30 0.480 0.870 -0.520
2020-06-30 0.301 0.862 -0.717
2020-03-31 0.319 0.871 -0.715

EYPT Price Target

For more insight on analysts targets of EYPT, see our EYPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.20 Average Broker Recommendation 1.4 (Strong Buy)

EYPT Stock Price Chart Interactive Chart >

Price chart for EYPT

EYPT Price/Volume Stats

Current price $3.39 52-week high $15.74
Prev. close $3.20 52-week low $2.97
Day low $3.09 Volume 124,200
Day high $3.46 Avg. volume 165,427
50-day MA $5.32 Dividend yield N/A
200-day MA $8.95 Market Cap 115.54M

EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio


EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.


EYPT Latest News Stream


Event/Time News Detail
Loading, please wait...

EYPT Latest Social Stream


Loading social stream, please wait...

View Full EYPT Social Stream

Latest EYPT News From Around the Web

Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purcha

Yahoo | November 16, 2022

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences: Guggenheim 4th Annual Immunology and Neurology DayForum: Fireside ChatDate: Monday, November 14, 2022Time: 3:20 p.m. ET Stifel 2022 Healthcare ConferenceForum:

Yahoo | November 7, 2022

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 2, 2022

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting and American Academy of Ophthalmology (AAO) 2022 Annual Meeting – – Net product revenue of $9.7 million in Q3 2022; a 13% increase from

Yahoo | November 2, 2022

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 2, 2022 to report its third quarter 2022 financial results and highlight recent corporate developments. To access the live conference call, please register

Yahoo | October 26, 2022

Read More 'EYPT' Stories Here

EYPT Price Returns

1-mo -35.55%
3-mo N/A
6-mo -61.74%
1-year -76.67%
3-year -76.94%
5-year -73.31%
YTD -72.30%
2021 86.02%
2020 -57.55%
2019 -17.99%
2018 75.00%
2017 -36.84%

Continue Researching EYPT

Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:

EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6685 seconds.